AIM： To examine whether polymorphisms in SULTIA1 and GSTP1 genes contribute to colorectal cancer development and whether they are associated with clinicopathological variables are not well identified. METHODS： We ex...AIM： To examine whether polymorphisms in SULTIA1 and GSTP1 genes contribute to colorectal cancer development and whether they are associated with clinicopathological variables are not well identified. METHODS： We examined the genotypes of 125 colorectal cancer patients and 666 healthy controls in a Swedish population by using PCR-restriction fragment length polymorphism （RFLP）. RESULTS： SULTIA1 ＊2/＊2 genotype （OR = 2.49, 95%CI = 1.48-4.19, P = 0.0002） and ＊2 allele （OR = 1.56, 95%CI =1.16-2.10, P = 0.002） had an effect on colorectal cancer susceptibility, while GSTP1 genotype was without effect. However, GSTP1 G-type predicted a worse prognosis in the patients independently of gender, age, Dukes＇ stage, growth pattern, and differentiation （P = 0.03）.CONCLUSION： Polymorphism in SULTIA1 may predispose to colorectal cancer and GSTP1 may be a biological indicator of prognosis in the patients.展开更多
基金Supported by grants from the Swedish Cancer Foundation and the Health Research Council in the South-East of Sweden
文摘AIM： To examine whether polymorphisms in SULTIA1 and GSTP1 genes contribute to colorectal cancer development and whether they are associated with clinicopathological variables are not well identified. METHODS： We examined the genotypes of 125 colorectal cancer patients and 666 healthy controls in a Swedish population by using PCR-restriction fragment length polymorphism （RFLP）. RESULTS： SULTIA1 ＊2/＊2 genotype （OR = 2.49, 95%CI = 1.48-4.19, P = 0.0002） and ＊2 allele （OR = 1.56, 95%CI =1.16-2.10, P = 0.002） had an effect on colorectal cancer susceptibility, while GSTP1 genotype was without effect. However, GSTP1 G-type predicted a worse prognosis in the patients independently of gender, age, Dukes＇ stage, growth pattern, and differentiation （P = 0.03）.CONCLUSION： Polymorphism in SULTIA1 may predispose to colorectal cancer and GSTP1 may be a biological indicator of prognosis in the patients.
